3rd Therapeutics Discovery
Convention Center, KSAU-HS. 10-11-12 October 2023
2023-10-10 03:00:00
Registration
Abstract Submission
  • ABSTRACT SUBMISSION
  • Home
  • About
    • OBJECTIVES
    • EXECUTIVE DIRECTOR MESSAGE
    • CONFERENCE CHAIRMAN MESSAGE
    • CONTACT US
  • SPEAKERS
    • SPEAKER LIST
    • MEET THE EXPERTS
  • PROGRAM
    • CONFERENCE PROGRAM
    • PRE-CONFERENCE WORKHOPS
  • EVENT DETAILS
    • REGISTERATION
      • ATTEND THE CONFERENCE
    • ABSTRACT SUBMISSION
      • ABSTRACT SUBMISSION
    • CONFERENCE DETAILS
      • ORGANIZERS
    • POSTERS
      • EVENT POSTER
      • POSTER TEMPLATE
      • POSTER GUIDELINES
      • POSTER REVIEW PANEL
    • CME
      • CME
  • Home
  • About
    • OBJECTIVES
    • EXECUTIVE DIRECTOR MESSAGE
    • CONFERENCE CHAIRMAN MESSAGE
    • CONTACT US
  • SPEAKERS
    • SPEAKER LIST
    • MEET THE EXPERTS
  • PROGRAM
    • CONFERENCE PROGRAM
    • PRE-CONFERENCE WORKHOPS
  • EVENT DETAILS
    • REGISTERATION
      • ATTEND THE CONFERENCE
    • ABSTRACT SUBMISSION
      • ABSTRACT SUBMISSION
    • CONFERENCE DETAILS
      • ORGANIZERS
    • POSTERS
      • EVENT POSTER
      • POSTER TEMPLATE
      • POSTER GUIDELINES
      • POSTER REVIEW PANEL
    • CME
      • CME

CONFERENCE PROGRAM

DAY 1
20 February 2023
Time(Riyadh Time)
Session 1: OPENING CEREMONY
9:00 – 9:25
Welcoming Remarks

• H.E. Dr. Bandar Alknawy, CEO-MNGHA, KSAU-HS President

• Dr. Ahmed Alaskar, KAIMRC Executive Director

• Dr. Mohamed Boudjelal, Conference Chairman

9:30 – 10:30
Keynote Opening Presentations

The Innovations from the COVID Pandemic That Will Make the Biggest Impact on Health by 2030 (30 min)
Dr. Ashley McKimm,
Editor-in-Chief, BMJ Innovations

Academic Drug Discovery in Practice – Learnings from the national Swedish SciLifeLab endeavourer with a twist towards targeted protein degradation (30 min)
Prof. Per I. Arvidsson,
Executive Director Drug Discovery & Development
Science for Life Laboratory Stockholm, Sweden

10:30 – 11:00
Coffee Break
 
Session2: COVID19: The New Era of Innovative Therapies and Vaccines

Chairperson: Dr. Majed Al Ghoribi, Infectious Diseases Department Chairman, KAIMRC

11:00 – 12:30

FIGHTING INFECTIOUS DISEASES AND TOXINS WITH RECOMBINANT ANTIBODIES (20 min)
Prof. Dr. Michael Hust, Technische Universität Braunschweig, Germany

Vaccines and therapies based on synthetic mRNA (20 min)
Dr. Steve Pascolo, Founder And CEO, Miescher Pharma GmbH, Zurich, Switzerland

Leukotriene inhibitors as promising treatment for COVID-19: a New Drug Discovery made in KSA (15 min)
Prof. Mohammed Al Ghobain, Consultant Pulmonologist at King Abdulaziz Medical City, Riyadh, KSA

Cnicin as an Anti-SARS-CoV-2: An Integrated in Silico and in Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics” (15 min)
Dr. Hani Abdullah Alhadrami, Consultant, King Abdulaziz University Hospital. King Fahad Medical Research Center, Jeddah, KSA.

Discussion (20 min)

12:30 – 13:30
Lunch Break
 
Session 3: mRNA Based Therapies and Vaccines for Cancer

Chairperson: Dr. Bader Alahmari, Chairman, Department of Blood and Cancer Research

13:30 – 15:00

Pathogenic Inflammation in COVID 19 (20 min)
Prof. Miriam Merad, Director of the Precision Immunology Institute at Mount Sinai School of Medicine, New York, USA

Anti-SARS-CoV-2 drug discovery: from drug repurposing to traditional Chinese medicine (20 min)
Prof. Hang Yang, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

From COVID-19 vaccines to broader therapeutics based on mRNA-encoded proteins (20 min)
Dr. Cesar Sanz Rodriguez, Vice President Medical Affairs – Europe, Middle East & Africa

Discussion 20 min

15:00 –15:30
Coffee Break
 
Session 4: mRNA Based Therapies for Rare Diseases

Chairperson: Dr. Bader Muzaini, Deputy Chairman, Genetic Department, KAIMRC

15:30 – 16:30

Genetic and Rare disease program (GARD): an opportunity for orphan diseases drug discovery and development (20 min)
Prof. Majid Alfadhel, Deputy Executive Director, Chairman, Genetics and Precision Medicine Department, King Abdulaziz Medical City, Riyadh, KSA

Rare Diseases Genetic Link (20 min)
Prof. Fowzan S Alkuraya, MD Principal Clinical Scientist and Senior Consultant, Chairman, Translational Genomics (Center for Genomic Medicine), King Faisal Specialist Hospital and Research Center, Riyadh, USA

Discussion 20 min

16:30 – 17:00
Coffee Break
 
KAIMRC’S Ph.D. Students Presentations

Chairperson: Dr. Zeyad Al Ehaideb, Team Leader Medicinal Plant, KAIMRC / Dr. Sameer Mohammad Senior Scientist KAIMRC

17:00 – 18:00

Investigating the role of ONECUT2 in brain tumour (10 min)

Ms. Rania Ahmed Haddadi,
Supervisor: Dr. Bahauddeen ALRfaei, Cellular Therapy and Cancer Research, KAIMRC

Functional significance of RNA binding proteins (RBPs) in Adipose biology (10 min)
Ms. Ghida Dairi
Supervisor: Dr. Sameer Mohammad, Experimental Medicine, KAIMRC

Hsp70 family interplay during heat-induced proteotoxic stress in modular neuronal cells (10 min)
Ms. Tahani Hassan Asiri
Supervisor: Dr. Shuja Malik, Experimental Medicine, KAIMRC

Commiphora myrrha constituents induce cytochrome P-450 enzyme metabolic enzymes in HepG2 cells: in vitro and in silico studies (10 min)
Ms. Amani Al-Sharidah
Supervisor: Dr. Zeyad Al Ehaideb, Natural Medicine, KAIMRC

Isolation, establishment, and characterization of natural and induced immortalized cancer cell lines from Saudi cancer patients (10 min)
Ms. Saba AL Subaie
Supervisor: Dr. rer. nat. Rizwan Ali, Team Leader of Light and Electron Microscopy Unit, KAIMRC

DAY 2
21 February 2023
 
Session 5: Immunotherapies for non-infection diseases

Chairperson: Dr. Fayhan Rogi , Immunotherapy Department Head, KAIMRC, Dr. Tlili Barhoumi, Cell-Flow Cytometry Platform, KAIMRC, KSA

8:30 – 10:00

BREAST CANCER IN DIABETES – DO ANTIGLYCATION COMPOUNDS HAVE A ROLE? (20 min)

Prof. Nessar Ahmed CSci FIBMS
Reader in Clinical Biochemistry, Department of Life Sciences, Manchester Metropolitan University, UK

Considerations for monoclonal antibody development by phage display (20 min)
Dr. Lim Theam Soon
Associate Professor at Universiti Sains Malaysia

Molecular/Precision Oncology Tumor Boards; NGHA local experience (15 min)
Dr. Kanan Alshammari
Director, Middle East – North Africa National Comprehensive Cancer Network (MENA NCCN) Coordinating Center King Abdulaziz Medical City, MNGHA

Identification of Neoantigens from Breast Tumor as Targets for Immunotherapy (15 min)
Dr. Mamoon Rashid
Department of AI and Bioinformatics
King Abdullah International Medical Research Center (KAIMRC)

Discussion 20 min

10:00 – 10:30
Coffee Break
 
Session 6: Repurposing and Cell based Therapies

Chairperson: Dr. Imadul Islam, Senior Research Scientist-Deputy Director Drug Discovery Program, KAIMRC / Dr. Bandar Alghanem, Head of Proteomics and Metabolomics, KAIMRC

10:30 – 12:30

The Fraunhofer 4 D concept for Health: combining drugs, device, diagnostics with data: how we can improve drug discovery to the benefit of the patients (20 min)
Prof. Dr. Claussen, Carsten
Director Fraunhofer IME ScreeningPort, Hamburg, Head of Fraunhofer “Initiative Medical Data Space”, Germany

Targeting cellular senescence to extend healthspan and resilience (20 min)
Paul D. Robbins Institute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN

Novel CAR-T cell Therapy Development and Mechanistic Studies. (20 min)
Prof. Peng li,
Principal Investigator, Guangzhou Institutes of Biomedicine and Health, CAS (Guangzhou, China)

Recent Trends on How to Overcome Multidrug Resistant Bacterial Infections’ (15 min)
Dr. Essam A. Tawfik; Director of the National Center for Pharmaceutical Technology at King Abdulaziz City for Science and Technology (KACST) Saudi Arabia

KAIMRC’S Discoveries of For MERS-CoV and SARS-CoV2 Inhibitors (15 min)
Dr. Nimer Mehyar, Head Protein-Enzymology Unit, KAIMRC-KSAU Researcher, KSA

Discussion 30 min

12:30 – 13:30
Lunch Break
 
Session 7: MAWHIBA Talents Presentation

Chairperson: Dr. Bahauddeen ALRfaei , Cellular Therapy and Cancer Research, KAIMRC

13:30 – 15:00

PINK1 has a major role in the survival of Medulloblastoma cells
(10 min)

Ms Aliya Nashmi
Mentor: Dr. Bahauddeen ALRfaei , KAIMRC

Effect of Environmental Factors on Monkeypox Cellular Infection (10 min)
Ms Ghada Alqarni
Mentor: Dr. Naif Alharbi , Ex-KAIMRC

Peroxisome Proliferator Activated Receptor α modulators as potential cancer therapy (10 min)
Ms Raghd AlGhamdi
Mentor: Dr. Arwa Alsuabit, KAIMRC

Functional study of RYR3 gene function using CRISPR system (10 min)
MS Jory Al Salamah
Mentor: Dr. Bader Muzaini, KAIMRC

Identification of a Rare Variant Associated with Congenital Heart Defect in a Saudi Family (10 min)
Ms. Layan Almojel
Mentor: Dr. Manal Alaamry, KAIMRC

15:00 – 15:30
Coffee Break
 
Session 8: AI Accelerating Drug Target, Antigens and Disease Pathway Discovery

Chairperson: Dr. Lamya Omair, Head of AI and Bioinformatics Department, KAIMRC

15:30 – 17:00

End-to-end AI drug discovery for kick-starting novel therapeutic programs (20 min)
Dr. Alex Zhavoronkov
Founder and CEO of Insilico Medicine (insilico.com)

Machine Learning Applications in Deconvoluting Hit Molecules into Fragments (20 min)
Dr. Shahul Nilar
Director, Computational Chemistry at Global Blood Therapeutics South San Francisco, USA

AI for in silico clinical trials and precision medicine. (20 min)
Dr. James Zou; Biomedical data science, CS and EE at Stanford University, USA

Dr. Ryan Copping ; Global Head of Data Science Acceleration (DSX); PD Data Sciences, Product Development (PD) Roche & Genentech, USA

Unlocking the protein universe to discover the medicines of tomorrow (20 min)
Dr.Naheed Kurji Co-founder, President & CEO;Cyclica Inc.

Discussion 10 min

17:00—17:30
Coffee Break
 
Closing Lectures: Research Funding and Regulatory Issues

Chairperson: Dr. Barrak Al Somaie, Director of Operation and Member of KAIMRC Funding Committee, KAIMRC, KSA

17:30 – 18:30

Clinical evaluation of new medicines in a regulatory setting (15 min)
Dr. Ahmed Alkhaldi , Head of clinical studies at the Saudi Food and Drug Authority, Riyadh, KSA

Determining drug profiles to improve clinical trial outputs.
Sheraz Gul, Fraunhofer IME ScreeningPort, Hamburg

KAIMRC Clinical Trial Setting (15 min)
Dr. Mohammad Bosaeed,, Infectious Disease Consultant, Department of Medicine, King Abdulaziz Medical city, Riyadh, KSA

Discussion 15 min

 
Panel Discussion: Lessons Learnt and Recommendations

Chairperson: Dr. Majid Aljeraisy, Chairman, Research Office and Director, Clinical Trial Services

18:30—19:30
Panelists:

Prof. Dr. Claussen, Carsten
Director Fraunhofer IME ScreeningPort, Hamburg, Head of Fraunhofer “Initiative Medical Data Space”, Germany

Dr. Mohammad Bosaeed,, Infectious Disease Consultant, Department of Medicine, King Abdulaziz Medical city, Riyadh, KSA

Dr.Naheed Kurji Co-founder, President & CEO;Cyclica Inc.

Dr. Alex Zhavoronkov Founder and CEO of Insilico Medicine (insilico.com)

Dr. Shahul Nilar
Director, Computational Chemistry at Global Blood Therapeutics
South San Francisco, USA

Dr. Ahmed Alkhaldi (15 min)
Head of clinical studies at the Saudi Food and Drug Authority, Riyadh, KSA

19:30—20:00
Closing Remarks

Dr. Ahmed Alaskar
Executive Director, KAIMRC, KSA

Therapeutics Discovery. 10-11-12 October 2023
Contact us

Contacts
KSAU-HS, Al Hars Al Watani, Ar Rimayah Riyadh 14611 Saudi Arabia
KAIMRC-Therapeutics@ngha.med.sa
LINKS
  • Therapeutics Discovery Conference
  • Objectives
  • About Therapeutics Discovery Conference
© 2021 KAIMRC - Advance Computing & Technologies, All Rights Reserved.